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1INTRODUCTION
Tuberculosis (TB) is an overall major   public health problem in the
world. Around one fourth of the global burden is contributed by India. The
incidence of tuberculosis in India is 28 lakhs and the mortality is 4.8 lakhs
in 2015 [1].
Tuberculosis is a highly contagious disease that is caused by
Mycobacterium tuberculosis bacteria. Mycobacterium tuberculosis spreads
easily from one person to another through the airborne spread of the
droplet nuclei.
Even with adequate treatment with anti tuberculosis drugs the
process of healing results in a variety of sequelae like fibrosis, cavitations,
bronchiectasis, bulla and calcification [2-4]. This can lead to various
symptoms and altered pulmonary function. These patients usually present
with symptoms like dyspnea, cough with production of sputum, wheeze,
fever and hemoptysis.
At present the functional impairment due to the various   tuberculous
sequelae is studied with tests like the six minute walk test or the shuttle
walk test. The pulmonary functional status is measured with the
spirometry. These tests help to determine the severity of the impairment
and to assess the quality of life in these patients. These tests also help in
2planning the pulmonary rehabilitation for these patients which could
increase the quality of life.
TB leads to poor ventilation and impaired gas exchange and an
overall decrease in functional status.
The six-minute walk   test more or less   reflects the ability of the
patients to perform their daily life activities than the laboratory tests, and it
is also well tolerated by majority of the patients. Smoking has been proved
to cause a decrease in lung function by many numbers of mechanisms.
Smoking is a predominant risk factor that affects   particularly   the
respiratory and cardiovascular systems leading to many respiratory
disorders or it may aggravate the respiratory symptoms. This study is done
to find if there is any significant relationship between the decreased lung
function or exercise capacity due to smoking in addition to the effects
caused by the tuberculosis sequelae. This   information may be used to
explain the harm of smoking and to   encourage the people to quit
smoking.
3AIMS AND OBJECTIVES
AIM:
To compare the respiratory function among the treated pulmonary
tuberculosis patients with sequelae among smokers and non smokers.
OBJECTIVES:
1. To   compare the spirometric values in treated pulmonary
tuberculosis patients   among smokers and non-smokers.
2. To   compare the six-minute walk distance in treated pulmonary
tuberculosis patients among smokers and non-smokers.
3. To assess the overall functional status in treated   pulmonary
tuberculosis patients presenting with sequelae among smokers and
non-smokers.
4REVIEW OF LITERATURE
EPIDEMIOLOGY:
Tuberculosis remains as the most important infectious disease that
produces a very high morbidity and mortality rates in our country.
TB BURDEN IN INDIA:
Tuberculosis was found to be   the third leading cause of years of
life lost (YLLs) in India.  The estimated incidence of TB (which is defined
as the number of new TB cases per year) is 2.8 million cases  per 100000
population .The estimated death rate  that is due to TB is 480,000. Around
5% of the TB cases are associated with   co infection with Human
immunodeficiency virus.
This study is aimed to determine the lung function and the exercise
capacity of the patients who had been treated with anti tuberculosis drugs
and presenting with sequelae that were demonstrated by chest radiography
and now presenting with respiratory symptoms.
PATHOGENESIS AND PATHOPHYSIOLOGY OF
TUBERCULOSIS:
Mycobacterium tuberculosis is an airborne infection that is caused
by the inhalation of the acid fast tuberculosis bacilli. Airborne droplets of
size 5- 10 microns reach the alveoli and the alveolar macrophages try to
contain the infection. These cells produce a number of cytokines and
chemokines that leads to control of the infection. If the host defense is
5impaired there may be a progression to active disease which is called
primary progressive tuberculosis. The pathogenesis of the disease depends
on the number and the virulence of the bacilli, immunity of the host.
Host defense factors:
1. The   activated macrophage
2. The capacity to stop the replication of bacilli intracellularly and
creating an encouraging intracellular environment, into the
unfavorable environment of caseous tissue.
Factors favoring the   bacillary growth:
1. The potential of the bacilli to multiply logarithmically inside the non
activated macrophages
2. The ability to multiply extracellularly within cavities.
The balance   between the host defense factors and the virulence of the
bacilli leads to the fate of the lesion.
6NATURAL COURSE OF TUBERCULOSIS:
7POST TUBERCULOSIS SEQUELAE:
Post tuberculosis sequelae include various types of radiological
manifestations and involve the pulmonary parenchyma, airways,
pulmonary vasculature, pleura, and the   mediastinum. According to KIM
et al the common findings in treated tuberculosis patients were
thin‑walled cavity, fibrosis, lung destruction or collapse, aspergillum,
bronchiectasis and bulla [3-6].
A mixed pattern is also commonly seen. So the functional
impairment that occurs due to post tuberculosis sequelae is due to the
sequence of these combined morphologic changes.
EFFECT OF SMOKING ON THE PATHOGENESIS OF
TUBERCULOSIS:
Tobacco smoke possesses a number of harmful substances which
may produce harmful effects on body. Tobacco smoke consists of about
more than 4000 identifiable compounds. The smoke is made of a fine
aerosol which contains particulate matters in the size range that gets
deposited in the airways and the alveoli.
The particles of smoke dust affect the function of respiratory
airways by different mechanisms. Tar   in the smoke produces   an irritant
effect on bronchial epithelium and destroys the cilia.  Beedi smoke may be
more harmful since   beedi is an unrefined form of tobacco when compared
to cigarettes.
8Prolonged use of tobacco and other environmental pollutants affects
the clearance of   the tracheo‑bronchial   secretion, so the tuberculosis
bacilli escapes the normal host defense and reach the alveoli [7]. Smoking
alters the action of pulmonary alveolar surfactants[8]. Nicotine acts directly
on nicotine acetylcholine receptors that are present in the macrophages and
leads to decreased intracellular tumor necrosis factor and thereby
ineffective  killing of M. tuberculosis [9]. A lot of studies have showed the
association between smoking and tuberculosis infection, and increased
mortality [10-14].
Deepti Rathee et al studied a total of 101 patients. Among them
about 53 patients were smokers and 48 were non smokers.  93.30% of
nonsmokers showed complete clearance of the infiltrates in chest X ray
and only 80% of smokers had complete clearance at the end of treatment.
At the end of treatment, complete radiological clearance of cavity
was observed in   91.1% nonsmokers and incomplete clearance of cavity
was seen in 80% of the smokers and 70% of the former smokers.  This data
implies that smokers and the former smokers have persistence of cavitation
as sequelae in   X‑ray after completion of treatment as compared to
nonsmokers [15].
9The common radiological pattern includes
1. Fibrosis
2. Cavitation
3. Bronchiectasis
4. Calcification
5. Bulla
6. Collapse /destroyed lung
7. Combined lesions
Fig -1
Chest x ray showing left destroyed lung
Heterogenous opacity of the left hemithorax with tracheal and mediastinal
shift .The right lung shows compensatory overinflation.
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Fig -2
Chest x ray showing fibrocavity
Fig -3
Chest x ray showing aspergilloma
Chest x ray shows monad sign in the right upper zone   characteristic of
fungal ball.
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Fig -4
Chest x ray showing cavity
Fig -5
Chest x ray showing bronchiectasis
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Fig -7
Chest x ray showing bulla
Fig -8
Chest x ray showing fibrosis
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Collapsed or destroyed lung may be visualized as loss of lung
volume of the affected side, higher location of the hemi diaphragm,
retraction of the hilum and displacement of the trachea and mediastinal
structures.
Cavity is usually thin walled. It may contain internal opacity with air
crescent sign that is a common sign seen in aspergilloma. Aspergillus
fumigatus is the most common fungus to colonize the remnant tuberculous
cavities in the lung. It also produces hemoptysis.
Pulmonary cavitation may cause alteration in the structure of   the
airways, and leads to airflow obstruction.
Bronchiectasis is the permanent dilatation and destruction of the
airways. It presents clinically as persistent cough with the production of
copious amount of sputum, it may also present as repeated episodes of
hemoptysis. Bronchiectasis also serves as a risk factor of pneumonia.
Bronchiectasis most commonly appears as small cystic lesions or
ring shadows. Destruction of elastic and muscular components of the
bronchial wall results in bronchiectasis, which is associated with airflow
obstruction [16]. Bronchiectasis usually produce obstructive pattern in
spirometry.
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IMMUNOLOGY IN TUBERCULOSIS:
This may also be due to the altered regulation of macrophages.
Macrophages are involved in killing the tuberculous bacilli and leads to
containment of infection in a site.  It also plays a role in the wound healing
and resolution and also plays a major role in the remodeling that produces
chronic airflow obstruction. Uninhibited Matrix metalloproteinase’s
expression and activity may leads to the destruction of lung tissue.
The immune system of the host is activated and it helps in
granuloma formation [17. A granuloma in tuberculosis contains a caseous
necrotic central core that is surrounded by a collection of cells like
macrophages, neutrophils, natural killer cells and T- and B-cells [17-19]. A
granuloma is a collection of a various types of inflammatory cells. It also
acts as active site of many enzymes like the proteases. The structure of the
granuloma consists of a central core that is made of macrophages that is
surrounded by lymphocytes. The macrophages on activation enlarge and
the margins become irregular to form a continuous sheet. These cells are
called epithelioid cells and the granuloma is now described as an
epithelioid cell granuloma. Epithelioid cells join to form the
multinucleated giant cells. In these giant cells the nuclei are arranged
predominantly along the periphery, which forms a rosette around the
central cytoplasm. These cells are called as the Langhans’ type of
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giant cells. During the progression of the disease, the granuloma undergoes
caseation to form a caseation necrosis . It indicates permanent destruction
of the tissue. Inside the caseum the low oxygen tension,acidic status  and
accumulation of the fatty acids inhibit multiplication of the bacilli. The fate
of the caseous foci differs in the hosts. It may organize completely and
turns into a fibrous scar or it may become calcified or ossified. It can
liquefy and leads to cavitation. Liquefaction occurs due to release of
proteolytic enzymes from neutrophils and macrophages.
STAGES OF PULMONARY TUBERCULOSIS:
There are Five Stages of Pulmonary Tuberculosis [20, 21].
Stage 1- Stage of no bacillary growth
The pathogenic TB bacilli are normally destroyed or inhibited by the
alveolar macrophages by phagocytosis.
Stage 2- Symbiotic stage
The bacilli multiply logarithmically inside the immature non
activated macrophages. The lesion, is now termed as tubercle.
Stage 3 - Stage of caseous necrosis
The growth of the bacilli is kept in check by the host immune
response to the antigens released by the bacilli.
Stage 4 – Stage of Cell-Mediated Immunity
If the cell mediated immunity is poor the bacilli escapes from the
periphery of the caseous necrosis and multiplies. The cytotoxic delayed
16
hypersensitivity immune response kills the macrophages, and leads to the
progression of the disease.  If the cell mediated immunity is good the
activated macrophages engulf and destroy the escaping bacilli and arrest
the lesions development at a subclinical stage.
Stage 5- Stage of liquefaction
The bacilli destroy the tissues and causes necrosis of the bronchial
wall which ruptures, and forms a cavity.
The most common symptoms that were encountered by the patients are
1. Cough
2. Breathlessness
3. Sputum production
4. Chest pain
5. Hemoptysis
6. Wheeze
Structural changes in the lung that occurs due to abnormal lung tissue
repair like fibrotic bands, distortion of the bronchovascular structures and
pleural thickening [16, 24] may result in airflow restriction in TB patients.
The infection with the tubercular bacilli results in the release of various
inflammatory mediators like the cytokines and chemokines that result in a
variety of structural alteration of the airways and the parenchyma.
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The inflammatory mediators and their consequent sequence are
explained in the following figure.
The major inflammatory mediators include
 Tumour necrosis factor – alpha
 Interleukin-1 beta
 Interleukin-6
 Interleukin-12
 Interleukin-18
 Interferon-gamma
 Matrix metalloproteinase
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ROLE OF INFLAMMATORY MEDIATORS IN TUBERCULOSIS:
19
Risk factors for development of sequelae:
1. Extensive involvement of the lungs
2. Delayed diagnosis
3. Inadequate treatment
4. Immuno compromised states like HIV  infection and chronic renal
failure
5. Smoking
6. Diabetes mellitus
20
SPIROMETRY
Types of spirometers
1. Flow-measurement devices
2. Volume-measurement devices
Flow-measurement devices:
This type of spirometer is used to measure the flow of the gas.They
produce signals in propotions to the gas flow, which is then converted into
volume .The flow is then divided into small time intervals usually in
seconds by the electronic software.
Subtypes:
1. Turbines
2. Pressure differential flow sensing
3. Pilot tube flow sensors spirometers
4. Hotwire anemometers
5. Ultrasonic sensors spirometers
Volume-measurement devices
Subtypes:
1. Water seal spirometer
2. Dry rolling seal spirometer
3. Bellows spirometer
Devices that were most frequently used in pulmonary function labs
are the pneumotachograph spirometer.
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Spirometry is used to assess the functional status of the lung by
measuring   the physiologic parameters like the forced vital capacity (FVC)
which is defined as the maximal volume of air that is forcefully exhaled
after a maximal inspiration, and forced expiratory volume in 1 second
(FEV1) which is the amount of air that is exhaled during the first second of
an FVC maneuver.
Both FVC and FEV1 are usually recorded in liters. Measuring these
values helps in identifying the airway obstruction. Small airway
obstruction can be identified earlier even before the development
significant clinical symptoms.
22
NORMAL FLOW VOLUME LOOP:
The flow volume loop is obtained by plotting the volume in x axis and
inspiratory and expiratory flows in the y axis.
The flow volume loop has two limbs inspiratory and expiratory limbs.
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SPIROMERTY IN VARIOUS DISORDERS:
24
Parameters FEV1 FVC FEV1/FVC
Obstructive disorders Decreased Normal Decreased
Restrictive disorders Decreased Decreased Normal
Mixed disorders Decreased Decreased Decreased
EFFECT OF SMOKING ON SPIROMETRY:
These patients often have decreased quality of life due to functional
impairment[22].
Sunita Nighute and Abhijit Awari et al in their study among 100
healthy male subjects included 50 smokers and 50 non-smokers and
showed in smokers, 36.0 % had obstructive changes followed by restrictive
changes in 8.0 % and the mixed changes in 4 %.  In the non-smokers group
98 % had normal spirometric results. All the pulmonary function
parameters such as FVC, FEV1, FEV/FVC, and PEF were notably reduced
in smokers.
They concluded that smokers had 18 times increased risk of having
impaired pulmonary functions when compared to non-smokers [25].
According to Bano et al smokers had 17.3 times increased risk of
having impaired pulmonary function when compared to non-smokers and
obstructive pulmonary impairment was the commonest in smoker [28 ,29].
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Study of Boskabady et al in Iran also supports that smokers have increased
frequency of respiratory symptom like cough, wheezing and breathlessness
and reduced values in spirometry [31].
SPIROMETRY IN POST TUBERCULOSIS PATIENTS:
Several earlier studies had suggested a notable correlation between
tuberculosis sequelae and airflow limitation.
All type of defects like obstructive, restrictive, and mixed pattern
may be established in post tubercular patients.
The various mechanisms that cause the spirometry defects are
illustrated in the following figure.
MECHANISM OF SPIROMETIC ABNORMALITIES IN
TUBERCULOSIS SEQUELAE:
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This diagram clearly explains the various mechanisms that lead to
obstruction and restriction.
Study by Ananya Panda et al was done among 101 patients who had
previous history of TB and chest X ray with sequelae. Among the total 101
patients,   nonsmokers were 77/101 (76.2%) and 24/101 (23.7%) patients
were smokers. Among them twenty three patients   were found to have
normal spirometric values without any defect. The most common
abnormality observed was restrictive defect, that was present in 40/101
(39.6%) patients, followed next by a mixed restrictive and obstructive
defect (34.7%). Purely obstructive defect was found only in 3 patients [31].
Study by Mohamed Manji et al study showed abnormal lung function in
371 (74 %) patients. Out of them 210 (42 %) patients had obstructive
pattern, restrictive pattern was seen in 65 (13 %) patients and 96 (19 %)
patients had mixed pattern. Recurrent TB   was associated with abnormal
lung function [33].
Sivaranjini S et al, in her study reported lower average of 6 minute walk
distance in post TB sequelae subjects than the normal population [33]. She
compared the 6 minute walk distance in sixty patients with tuberculosis
sequelae and 60 people from the normal population. The result showed that
the TB sequelae study group had a lower average six minute walk distance.
Exercise hypoxia may have lead to the decreased 6MWD noted in the TB
sequelae group [34].
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Rajasekaran S et al., described the occurrence of post-TB asthma in
50.9% of   patients within one year of completing the anti tubercular drugs
[41]. Krishna K et al., mentioned that obstruction was  the most common
impairment in his of follow up study [42].
Meyyappan D, et al reported that mixed (39%) pattern was the most
common abnormality in spirometry followed by obstruction (24%) and
restriction (18%). In his study conducted in the Institute of Thoracic
Medicine, Chennai, 98% of the patients had impaired exercise capacity.
About 41.5% had mild impairment; moderate impairment was seen in
39.5% and severe impairment in 17%. The pulmonary function
abnormalities correlated positively with the radiological severity [48].
Singh B, et al studied the spirometric values in 48 patients and pointed out
that all  the three  forms of pulmonary function impairment  were observed
in the study group, but  obstructive pattern  was the dominant  type than
other types[49].
Agarwala A et al had done a cross-sectional study in Medinipore Medical
College among 72 patients who had post tubercular fibrosis.  In his study,
thirtyeight patients (52.7%) had an obstructive ventilatory defect, ten
patients (13.8%) had a restrictive pattern and 12 patients (16.6%) revealed
a mixed obstructive and restrictive pattern. 16.6%). Lung function was
normal only in 12 patients (16.6%) [50].
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AvradipSantra et al studied a total of 138 patients. Dyspnea was the
predominant symptom which was observed in 95.65% cases followed by
cough in 89.85% cases and expectoration in 75.36% of patients. A positive
correlation was found between the extent of the radiologic lesion and the
severity of airflow obstruction. Obstructive pattern was seen in 27.54%
patients and 72.46% patients showed mixed pattern [46].
Thus many studies done earlier in post tuberculosis patients show
the association of airflow limitation to the radiological lesions.
Tuberculosis is considered as the major risk factor for the development of
obstructive lung disease.
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FACTORS AFFECTING THE OUTCOME OF LUNG FUNCTION
IN TREATED PTB PATIENTS:
30
Gender:
The impairment of lung function is found to be greater among the
males when compared to females. This may be due to the increased
smoking habit and occupational exposure to various substances that
typically affects the respiratory system.
Number of TB episodes:
The extent of radiological lesions was more in previously treated
patients. The severity of obstruction or restriction pattern was greater and
is directly related to the number of TB episodes.
Extent of disease in radiology:
Ananya Panda et al studied  the correlation between the  findings in
radiography  and pulmonary function tests  in  pulmonary tuberculosis
sequelae patients  and showed a significant correlation between the  grades
of dyspnea and lesions like  fibrosis , bronchiectasis etc . Restrictive defect
was the more prevalent finding that was found in 39.6% followed the by
mixed defect in 34.7%.
Dhipu Mathew et al in her study among a total of 75 treated
pulmonary tuberculosis patients observed that the most common symptom
was breathlessness. Chest x ray with involvement of  1 or 2 zones  were
seen in  40 (53.3%) and 3 and more  zones involvement  were  in  35
(46.7%). About 51 (68%) showed a restrictive pattern, 10 (13.3%) showed
an obstructive pattern and 14 (18.7%) revealed a mixed pattern in
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spirometry [51].Thus many studies have demonstrated the inverse
relationships between the the lung function and the extent of the lung
involved.
SIX MINUTE WALK TEST:
The 6MWT is an easy, feasible test that can be conducted without
any special equipment even   in the peripheral centers. There is no need for
specific training for the technicians.
Walking is a day to day simple activity and difficulty or decreased
walking capacity implies the degree of impaired functional status of the
patient. 6MWT is a better index of the patient’s ability to carry out the
daily activities [54].
Indications:
The major indication for six minute walk test is to evaluate the
effectiveness of medical interventions in patients with lung disease. It is
also used in measuring the one- time extent of the functional status of
patients, and also serves as the predictor of morbidity and mortality.
This test measures the distance that can be walked quickly by a
patient on a level, hard surface in 6 minutes duration. It assesses   the
simultaneous responses of all the various system that were involved during
the period of exercise like the pulmonary and cardiovascular systems,
systemic circulation and muscle metabolism [54].
32
Six minute walk test is the commonly conducted test for the
evaluation of preoperative and postoperative functional status. It can also
be used   for the assessment of   the response to the therapeutic
interventions for pulmonary and cardiac diseases [54].
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MATERIALS AND METHODS
The present study was carried out in the Department of Thoracic
Medicine, Tirunelveli Medical College Hospital, Tirunelveli after the
approval from the Ethical Committee of the Tirunelveli medical college.
STUDY DESIGN:
Prospective cross sectional study
STUDY DURATION:
Eighteen months
STUDY POPULATION:
The patients included in the study were selected from our
department outpatient population. These patients were selected by the
following inclusion and exclusion criteria
INCLUSION CRITERIA:
1. Patients who were previously treated as sputum positive tuberculosis
and completed treatment according to the guidelines of RNTCP
2. Sputum smears for AFB negative at present
3. Chest x ray showing tuberculosis sequelae
EXCLUSION CRITERIA:
1. Patients with BP more than 180/120 mm Hg
2. Resting heart rate more than 120/min
3. Patients with chest pain
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4. Patients with vascular/musculoskeletal abnormalities in lower
extremities.
5. Patients with respiratory failure
6. History of cardiac or abdominal surgery within six months
CONSENT:
A detailed written informed consent from all the participants was
obtained after clearly explaining the purpose of the study.
HARM AND BENEFIT:
The study causes no harm to the participants. Some may have
dizziness or breathlessness during the spirometry procedure, but it is rare.
The indirect benefit includes awareness about their current status and to
plan for the rehabilitation to improve the quality of their life.
RESEARCH VARIABLES STUDIED:
A. Independent variables
1. Age
2. Sex
B. Dependent variables
1. Smoking
2. Spirometry
3. Distance walked in 6 minutes
4. Body mass index
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MATERIALS USED IN THE STUDY
 Consent form
 Computerized spirometer
 Disposable mouth pieces
 Stop watch
 Sphygmomanometer
 Measure tape
 Chalk
 Pulse oximeter
METHODOLOGY:
Informed written consent is obtained from all the patients included
in the study. Detailed history of the patients was obtained regarding the
symptoms, previous anti tubercular treatment history, smoking history.
Spirometry and six minute walk test were conducted in the same day.
Patients were grouped into two groups as smokers and non smokers.
Severity of smoking was assessed using ‘Smoking Index’ (SI). It is
defined the number of beedi or cigarettes smoked per day that is multiplied
by duration of smoking in years. Smokers were categorized as
 Mild smokers (SI<100)
 Moderate smokers (SI=100-300)
 Heavy smokers (SI>300) [53].
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BMI:
The height of all the participants was measured in centimeters and
weight was recorded in kilograms. BMI is calculated based on the NICE
guidelines.
BMI(kg/m2) CATEGORIES
< 18.5 Underweight
18.5-24.9 Good
25.0-29.9 Overweight
>30 Obese
ATT HISTORY:
Detailed history about the previous anti tubercular drugs which
includes the treatment duration , category of drug , sputum AFB status at
the starting of the treatment , private or government regimen  were
obtained.
RADIOLOGICAL FINDINGS:
Chest X ray was taken for all the patients. The lung field is divided
into 6 zones. Space up to the lower border of second rib  was considered as
the  upper zone , Space up to the lower border  fourth rib were considered
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as  the middle  zone and the space below is  considered as the  lower  zone
on both the sides .
SPIROMETRY:
Lung functions were measured with the Minispiro II winspiro PRO
5.7 spirometer. Disposable mouthpiece was used for each patient and was
discarded after every use. Spirometry was performed in the sitting posture.
The forced expiratory maneuvers were demonstrated to the participants in
local language. Pre and post bronchodilator spirometric maneuvers were
done for all the patients. The results were recorded as absolute volumes in
liters. The measurements included in the study were forced vital capacity
(FVC), forced expiratory volume in 1 second (FEV1), ratio of FEV1 and
FVC and peak expiratory flow rate.
The classification of the spirometric values as normal, obstructive,
restrictive and mixed was done based on the ratio of FEV1/FVCas
recommended by the American Thoracic Society [14] .The severity of
obstruction and restriction was classified based on the FEV1‑based criteria
recommended by the European Respiratory Society and the American
Thoracic Society [6].
1. Normal - FEV1/FVC ratio of >70% and an FVC of >80% predicted
2. Obstruction - airway obstruction was defined as an FEV1/FVC ratio
of <70% and an FVC of >80% predicted
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3. Mixed combined defects- FVC of <80% predicted and an
FEV1/FVC ratio of <70%
4. Restriction -restrictive defects as an FEV1/FVC ratio of >70% with
an FVC of <80% predicted.
SEVERITY OF OBSTRUCTION:
Impression Predicted  FEV1 %
Normal >80
Mild obstruction 70-79
Moderate obstruction 60-69
Moderately severe obstruction 50-59
Severe obstruction 35-49
Very severe obstruction <35
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SEVERITY OF RESTRICTION:
Impression Predicted FVC %
Mild restriction 70-80
Moderate restriction 60-69
Moderately severe restriction 50-59
Severe restriction <50
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6-MINUTE WALK TEST:
The test was carried out as cited by the   American Thoracic Society
guideline.
o 30 meter long hospital corridor was selected and every meter
is marked by a line.
o Participants were explained about the use of the test and
were instructed to walk in their normal pace from one end to
the other end and to cover as much distance as possible during
the six minute time. Encouragement through words was not
done while the patient was walking and only the left over
duration was pointed out every minute.
o Participants were permitted to stop in case they developed any
symptoms like chest pain, giddiness or leg cramps.
o They were allowed to continue the walk if it was possible for
them. The distance covered was recorded at 2, 4, and 6
minutes.
o Heart rate, blood pressure, oxygen saturation and Borg
dyspnea scale were recorded both before and after completion
of the test.
41
BORG DYSPNEA SCALE:
0 Nothing at all
0.5 Very very  slight (just noticeable)
1 Very slight
2 Slight
3 Moderate
4 Somewhat severe
5 Severe
6 ↓
7 Very severe
8 ↓
9 ↓
10 Very very  severe
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DATA ANALYSIS:
The data’s were collected and statistical analysis was done using
SPSS software version12.0.
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OBSERVATION AND RESULTS
AGE AND SEX DISTRIBUTION OF PATIENTS:
Among 100 patients included in the study, 45 were smokers and 55
were non smokers. Of them 79% of the patients (n= 79) were male and
21% of the patients (n= 21) were female.
They were classified into two group’s base on the smoking history.
Group I were smokers and group II were non smokers.
CHART -1: DISTRIBUTION OF PATIENTS:
45%
55%
DISTRIBUTION OF PATIENTS
Smokers Non Smokers
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GROUP I:
Among patients in group I, all were males (n=45) and none of them
were female.
The mean age group of the patients was 57 years. About 7% (n= 3)
of the patients were in the age group of 31-40 years of age ,9%(n=4) of the
patients were in the age group of 41-50 years ,44   % (n= 20) of the
patients were in the age group of 51 – 60 years, 31 % (n=14) of the patients
were in the age group of 61 – 70 years of age and 9%(n=4) ) of the patients
were  >70 years of age.
Group II:
Among patients in group II, thirty four patients (62%) were male
and twenty one patients (38 %) were female.
The mean age group of the patients was 51. About 5%(n=3) of the
patients were in the age group of 21-30 years of age, 15% (n= 8) of the
patients were in the age group of 31-40 years of age, 22% (n=12) of the
patients were in the age group of 41-50 years about 29%   (n= 16) of the
patients were in the age group of 51 – 60 years. 25% (n=14) of the patients
were in the age group 61 – 70   years of age and 4% (n=2) of the patients
were >70 years of age.
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CHART -2: AGE DISTRIBUTION OF THE PATIENTS
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SYMPTOMS OF PATIENTS:
The common symptoms that were   observed among the post tuberculosis
sequelae   patients include cough (86%), breathlessness (66%), sputum
production (66%) and hemoptysis in 6 % of patients. Breathlessness was
observed in more number of patients (91%) in group I.
CHART- 3: SYMPTOM PATTERNS AMONG THE TWO GROUPS
Cough Sputum Dyspnea Wheeze
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TABLE-1: DISTRIBUTION OF PATIENTS BY SMOKING INDEX:
SMOKING INDEX NUMBER OF
PATIENTS
PERCENTAGE
<100 1 2
100 – 300 10 22
300 34 76
CHART-4: BMI STATUS OF THE PATIENTS AMONG THE TWO
GROUP
In non smokers group, 41 % (n=23) of the patients were in
underweight category, 41 % (n=23) of the patients were in normal and 18
% (n=9) were in overweight category.
In smokers group, 24% (n=11) patients were in underweight
category, 66% (n=30) in normal and 10% (n=4) were in overweight
category.
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Chart-5: DISTRIBUTION OF PATIENTS AMONG CAT I AND
CAT II ATT
Chart-6: SMOKING AND ATT CATEGORY AMONG THE TWO
GROUPS
The chart explains that smoking leads to impaired healing process
and may increase the risk of failure or relapse thereby increasing the need
for number of treatment.
63
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TABLE-2: SMOKING AND ATT CATEGORY
CROSSTABULATION
SMOKING
ATT category
P valueCAT I CAT II
NON SMOKERS 46 9
<0.0001SMOKERS 17 28
About 28 patients among smokers group had category II ATT but only 9
patients among non smokers group had category II ATT. The difference is
statistically significant (P value l < 0.0001).
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TABLE-3: COMPARISON OF CATEGORY OF ATT &
SPIROMETRY:
Parameter ATT N Mean
Std.
Deviation P value
FVC CAT I 63 2.20 0.54
<0.0001CAT II 37 1.78 0.53
FEV1 CAT I 63 1.63 0.46
<0.0001CAT II 37 1.04 0.44
FEV1_FVC CAT I 63 75.32 13.97
<0.0001CAT II 37 60.50 11.41
PEF CAT I 63 3.3694 1.27693
<0.0001CAT II 37 2.1122 1.14051
6 MWT
DISTANCE
CAT I 63 363.76 34.87
<0.0001CAT II 37 309.46 37.79
All the parameters of spirometry FVC, FEV1, FEV1/ FVC & PEF
were reduced in patients who had multiple treatments. The differences for
all the values were statistically significant (P < 0.0001).
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COMPARISON OF CATEGORY OF ATT & DISTANCE WALKED:
The mean distance walked by patients with history of CAT I was 363.7 m
and the mean distance walked by patients with history of CAT II was
309.46 m (P < 0.0001).
CHART-7: COMPARISON OF CATEGORY OF ATT & DISTANCE
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RADIOLOGICAL LESIONS AMONG   GROUP I & II:
In our study smokers had a more   number of bilateral lesions in
chest x ray 42 %( n=19) than non smokers group 9 % (n =5).
TABLE-4: COMPARISON OF SIDE INVOLMENT IN CHEST X
RAY IN BOTH GROUPS
UNILATERAL % BILATERAL %
SMOKERS 26 58 19 42
NON SMOKERS 50 91 5 9
CHART-8: DISRTIBUTION OF LESIONS IN SMOKERS GROUP
38%
62%
SMOKERS
UNILATERAL
BILATERAL
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CHART-9: DISRTIBUTION OF LESIONS IN NON SMOKERS
GROUP
NON SMOKERS
UNILATERAL
BILATERAL
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TABLE-5: COMPARISON OF RADIOLOGICAL LESIONS &
SPIROMETRY:
Parameters
Side of
lesion
No.of
patients Mean
Std.
Deviation P value
FVC U/L 76 2.18 0.53
<0.0001B/L 24 1.62 0.49
FEV1 U/L 76 1.55 0.50
<0.0001
B/L
24
0.98 0.41
FEV1_FVC U/L 76 72.75 14.19
<0.0001B/L 24 60.63 13.39
PEF U/L 76 3.2228 1.31960
<0.0001B/L 24 1.8954 .97866
Distance
walked
U/L 76 358.47 33.51
<0.0001B/L 24 296.79 42.70
All the parameters of spirometry such as FVC, FEV1, FEV1/ FVC & PEF
were reduced in patients who had bilateral lung involvement in chest X ray
.The difference for all the values were statistically significant (P < 0.0001).
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CHART-10: COMPARISON OF RADIOLOGICAL LEISONS & 6
MWT DISTANCE:
The mean distance walked by patients with unilateral lung
involvement   was 358.47 meters and the mean distance walked by patients
with bilateral lung involvement   was 296.79 meters.  The difference is
statistically significant (P < 0.0001).
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CHART-11: CHEST X RAY PATTERNS AMONG SMOKERS AND
NON SMOKERS:
SMOKERS & ZONES INVOLVED:
In smokers group the number of patients with 1 zone involvement is
thirtynine (71 %), 2 zones involvement is fifteen (27%), 3 zones
involvement is one (1 %), none of the patients had involvement of 4 or
more zones.
In non smokers group the number of patients with 1 zone
involvement is eleven (24 %), 2 zones involvement is seventeen (37%), 3
zones involvement is ten (1 %) and seven (15 %) patients had involvement
of 4 or more zones.
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TABLE-6: DISTRIBUTION OF ZONAL INVOLVEMENT IN
RADIOLOGY AMONG SMOKERS AND NON SMOKERS:
NO.OF
ZONES
Group 1 Group 2
P value
Number Percentage Number Percentage
1 11 24 39 71 <0.0001
2 17 38 15 27 <0.0001
3 10 22 1 1 <0.0001
4 7 16 0 0 <0.0001
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CHART-12: COMPARISON OF NUMBER OF ZONES INVOLVED
AMONG THE TWO GROUPS
The above diagram explains that the radiological extent of disease in
term of number of zones involved is greater among smokers than non
smokers (P < 0.0001).
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TABLE-7: COMPARISON OF NUMBER OF ZONES
INVOLVED AMONG THE TWO GROUPS
Spirometry
values
Number of
Zones N Mean
Std.
Deviation P value
FVC
1 50 2.23 0.54
<0.00012 32 2.09 0.463 11 1.58 0.51
4 7 1.28 0.32
FEV1
1 50 1.68 0.51
<0.00012 32 1.35 0.333 11 0.89 0.28
4 7 0.63 0.13
FEV1_FVC
1 50 78.17 13.34
<0.00012 32 64.95 10.743 11 57.75 11.43
4 7 51.66 5.07
PEF
1 50 3.5968 1.27311
<0.00012 32 2.6078 1.005863 11 1.6600 1.00649
4 7 1.2671 .45948
Distance
walked
1 50 370.84 29.29
<0.00012 32 338.34 24.513 11 287.82 32.18
4 7 261.71 29.93
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CHART-13: COMPARISON OF NUMBER OF ZONES & 6 MWT
DISTANCE:
The mean distance walked by patients with four zones involvement
is 261. 71 m and the mean distance walked by patients with one zone
involvement were 370.84 meters. The difference is statistically significant
(P < 0.0001).
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CHART-14: COMPARISON OF SPIROMETRY AMONG
SMOKERS & NON SMOKERS:
19 18
11
7
2
13
4
26
0
5
10
15
20
25
30
NORMAL  OBSTRUCTION RESTRICTION MIXED
Nu
mb
er 
of 
Pa
tie
nts
NON SMOKERS
SMOKERS
62
CHART-15: PATTERN OF SPIROMETRY IN SMOKERS
In our study, the commonest spirometric pattern in smokers group was
mixed pattern.
Mixed pattern - 58% of patients (n= 26)
Obstructive pattern - 29 % of patients (n= 13)
Restrictive pattern - 9 % of patients (n= 4)
Normal - 4 % of patients (n=2)
PATTERN OF SPIROMETRY IN SMOKERS
Mixed
Obstruction
Restriction
Normal
63
CHART-16: PATTERN OF SPIROMETRY IN NON SMOKERS
Among non smokers group the distribution of the spirometric pattern was
as follows.
Normal pattern - 34% of patients (n= 19)
Obstructive   pattern - 33% of patients (n= 18)
Restrictive pattern - 20% of patients (n= 11)
Mixed pattern -1 3% of patients (n= 7).
PATTERN OF SPIROMETRY IN NON SMOKERS
Mixed
Obstruction
Restriction
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CHART-17:MEAN 6 MWT   DISTANCE AMONG SMOKERS &
NON SMOKERS:
The mean distance walked by non smokers was 368.16 + 30.19
meters and the mean distance walked by smokers was 313.73+40.73
meters. The difference between the two groups is   54.43 meters (P <
0.0001).
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CHART-18: COMPARISON OF 6 MWT DISTANCE AMONG
SMOKERS & NON SMOKERS
In smokers group, 13% of patients walked in the range of 201-300
meters, 69 % of patients walked in the range of 301-400 meters and 8
patients discontinued the test due to breathlessness.
In non smokers group 3 % of patients walked in the range of 201-
300 meters, 85% % of patients walked in the range of 301-400 meters and
12 % of patients walked more than 500 meters.
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TABLE-8: COMPARISON OF SPIROMETRY AND 6 MWT
DISTANCE WITH SMOKING INDEX:
Spearman's correlation FVC FEV1 FEV1_FVC PEF
Distance
walked
Spearman
smoking
index
Correlation
Coefficient
-.450** -.687** -.585** -.604** -.691**
Sig.
(2-tailed)
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001
All the parameters of spirometry like FEV1, FVC, FEV1/FVC, PEF had
a significant negative correlation with the smoking index. As the smoking
index increased the Spirometry and the 6 minute walk test distance
decreased.
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DISCUSSION
Pulmonary TB leads to various long term lung complications like
pulmonary fibrosis, bronchiectasis, aspergilloma, airway stenosis and
chronic airflow obstruction [70] and it has been also demonstrated as a risk
factor for lung cancer [71] . These sequelae often lead to complications like
recurrent respiratory infections , hemoptysis , pulmonary hypertension and
corpulmonale . They also affect the normal daily activities and results in
poor quality of life, increased financial burden and negative psychological
effects in these patients.
In our study a total of 100 patients were included and they were
categorized into two groups, group I – smokers (45%) and group II – non
smokers (55%). In smokers group none were female and in group II, 34
were male and 21 were females.
The most common age group observed was between 51 -60 years.
The mean age group of the patients was 51. About 29% (n= 16) of the
patients were in the age group of 51 – 60 years. 25% (n=14) of the patients
were in the age group of 61 – 70   years.
Among smokers group 1 patient was mild smokers, 10 were
moderate smokers and 34 were severe smokers.
Many studies that have been done earlier had demonstrated the link
between the pulmonary sequelae and the impaired lung function.
68
Based on literatures, the common symptoms of patients presenting with
sequelae  include cough (90%) ,breathlessness (80%) and  sputum
production (86%) , In our study most common symptoms that were
observed among the post tuberculosis sequelae  patients  includes  cough
(86%) ,breathlessness (66%), sputum production (86%) .
In a similar   prospective study conducted by Long R   in 25 patients
with post TB sequelae, emphysematous change (36%), bronchiectasis
(40%), distortion of bronchi (56%), and fibrosis (64%) were present as
common type of radiological lesions. Structural changes   and impairment
of   lung function were more common in patients who had cavitary lesion
than in patients with the non-cavitary lesion [16]. In our study we observed
bronchiectasis (27%), fibrosis (25%) and combined lesions were observed
in 43% of patients.
Racilet al in his study showed that the residual radiological severity
score was more among smokers than non smokers. This is similar to our
study which shows a more number of lobe involvements in smokers group
[78].
In non smokers group the number of patients with 1 zone
involvement is thirty nine (71 %), 2 zones involvement is fifteen (27%), 3
zones involvement is one(1 %) and  none of the patients had involvement
of 4 or more zones. In smokers group the number of patients with 1 zone
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involvement is eleven (24 %), 2 zones involvement is seventeen (38%), 3
zones involvement is ten (22 %) and seven (16 %) patients had
involvement of 4 or more zones.
In our study 28 patients among smokers had category II ATT but
only 9 patients among non smokers had category II ATT. The difference is
statistically significant (P value less than 0.0001).
F.C. Di Naso et al in his study of functional evaluation in patients
with  tuberculosis sequelae , concluded that the pulmonary function of the
patients in the group with  multiple treatments (CAT  II ATT ) showed
significant reductions in FVC and FEV1, when compared to the group with
only one treatment ( CAT I ATT). In patients with CAT II ATT, 75% of
patients had severe respiratory distress, compared to 13.3% of patients who
had CAT I ATT. Patients with CAT I ATT showed radiological
abnormalities with minimal involvement in 46.7% of cases and patients
with CAT II ATT had severe impairment in 83.7% of cases as evaluated
by radiography. Mixed ventilatory defects were more prevalent in the
group with multiple treatments [35].
This is similar to our study where patients with history of cat II ATT
had more number of lobes involved in the chest x ray and decreased
spirometric values.
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Laxmankumar soni et al in his study of Impact of pulmonary
tuberculosis sequelae on functional status observed that patients with CAT
II ATT had lower values of FEV1 %, FVC% and FEV1/FVC. Patients
with CAT II ATT also  showed greater functional impairment, as the
average distance walked in six minute walk test  was 78.21 meter lesser
than patients with CAT I ATT. This suggests that multiple times treated
and cured TB patients suffer significantly more clinical, radiological and
functional abnormality when compared to single time treated patients [57].
SPIROMETRY:
In our study most common spirometric pattern was mixed pattern
(58%), followed by obstruction (29%). In smokers group the commonest
spirometric pattern was mixed pattern .It was observed in 58% of patients
( n= 26) followed by obstruction in 29 % of patients  (n= 13) and
restriction in 9 % of patients  (n= 4 ) and normal  in 4 % of patients  (n=2)
.Among non smokers group normal pattern was observed in 34% of
patients  (n= 19 ) followed by obstruction  in 33% of patients  (n= 18)
restriction  in 20% of patients (n= 11)  and mixed pattern in  13% of
patients (n= 7) .
The difference is statistically significant (P value < 0.0001). According to
the spearman correlation smoking index has significant negative
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correlation between spirometry and the distance walked (P value <
0.0001).
The findings were similar to the study conducted by Avradip
Santra et al in which obstructive pattern was established in 27.54% cases
and  mixed pattern in72.46% [73].
Nimit V Khara et al in his study  showedmixed  ventilatory defects
in 47% , restrictive  ventilatory defect in  37% ,  obstructive  in 9 % [74]
Neeta Singh et al in their study among 51 multidrug resistant TB patients
who had completed the treatment showed that about 78% had persistent
respiratory symptoms, around 98% had residual lesions in radiology, and
96% demonstrated ventilatory defects. Among them 66% had mixed type
of ventilatory abnormality while 19% showed pure restriction and 11%
showed pure obstruction after completion of treatment [72].
The result was in contrast to the studies done by Bhola Singh et al,
verma et al   and  Abinash Agarwala et al .
Verma et al in their study among 92post PTB individuals found
restrictive pathology in 37 and mixed patterns in 21 patients [38].
Bhola Singh et al showed that obstructive defect (56.25%), was more
common than the other types and restrictive impairment was seen only in
10.42% of cases [49].
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Manji et al demonstrated in their study, the presence of individual
patterns of impairment were 42%, 13%, and 19% for obstructive,
restrictive, and mixed patterns respectively [33].
Santhosh Kumar et al in his study of Evaluation of Pulmonary
Impairment by spirometry in post pulmonary tuberculosis patients showed
that obstructive pattern was seen in 37 patients (45.1%), restrictive pattern
in 21 patients (25.6%) and mixed pattern in 24 patients (29.3%).
Patil et al in his study of spirometry assessment of symptomatic
post TB cases observed that obstructive pattern was the predominant type
and was documented in 42% cases, mixed pattern in 14%, and normal
spirometry in 46% cases [81].
Many previous studies have showed a notable association of airflow
obstruction in post tubercular patients. In fact many studies have proved
that tuberculosis serves as an independent risks factor for the development
of obstructive pattern in spirometry.
The increased occurrence of mixed or obstructive pattern of
ventilator defect may be due to the dual effect on ventilation and perfusion
by the tubercular bacilli. In previously treated TB patients, the airways
were   structurally abnormal which leads to reflex vasoconstriction and
hypoxemia. Also, the bacilli directly cause arteritis and thrombosis that
modifies perfusion. These  patients  also  have other abnormalities like
pleural thickening, fibrosis of the parenchyma, and atelectasis which serves
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as an additional  factor for  the predominant mixed  pattern rather than the
pattern of pure airflow obstruction[4,16]
EFFECTS OF SMOKING IN PTB:
Nicotine turns off the Tumour Necrosis Factor-alpha (TNF-α)  that
was usually produced by the lung macrophages, which  leads to increased
lung structural abnormalities [77] .The  mycobacterial antigens act as a co-
factor  along with smoking and other environmental factors such as
biomass fuel or pollution, which leads to chronic airway inflammation that
results in bronchial narrowing with or without destruction of the
parenchyma. Smoking alters the normal host response and the chronic
inflammation may produce parenchymal tissue destruction and it also
impairs the normal repair and defense mechanisms leading to radiological
sequelae.
Due to the up regulation of different proteases like matrix
metalloproteinase and defective protease control mechanism there is
increased destruction of lung parenchyma that leads to airflow obstruction.
Matrix metalloproteinase also leads to cicatrisationof lung tissue and
fibrotic changes that were responsible for associated restrictive disorder.(76)
Anup Banur et al in his study on Effects of Smoking on Spirometry
concluded that the values of forced expiratory volumes like FVC, FEV1,
FEV1/FVC were lower in beedi smokers. The values of forced expiratory
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volumes like PEFR and MEF75 were also lower in beedi smokers
compared to non smokers [82].
Similar observations were obtained in the studies   by Padmavathy
KM and Bano R et al which showed that the obstructive lung changes
were most common in smokers than non smokers [28 ,83].
SIX MINUTE WALK TEST:
In our study out of 45 smokers, 8 patients stopped the six minute
walk test due to breathlessness and palpitation whereas none of the patients
stopped walking during the six minutes in non smokers group. The mean
distance walked by non smokers group were 368.16 + 30.19 meters and the
mean distance walked by the smokers group were 313.73+40.73 meters.
The difference between the 2 groups is 54.43 meters (P < 0.0001). The
mean distance walked by patients with unilateral lung involvement was
358.47 meters and the mean distance walked by patients with bilateral lung
involvement   was 296.79 meters.  The difference is 61.7 meters (P <
0.0001).
This is similar to the study done by S. Sivaranjini et al who showed
that 6 min walk test distance was significantly low among smokers [34].
Lakshmansoni et al in their study showed that there was a significant
functional impairment in post tuberculous sequelae patients and the
distance walked by them were significantly lower [79]. This finding
corresponds to our study.
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Mikhail chushkin et al in their study proved that there was a
significant correlation between the 6MWT and the spirometry and the
symptoms [64] .This is agreed in our study.
Marcos DP et al in their study of functional assessment of patients
in drug resistant TB showed that the distance completed in six minute walk
test is lower in treated patients [85].
During the six minute walk test the myocardial oxygen demand of
the patient increases. In smokers there could be functional anemia due to
the increased levels of carbon monoxide that leads to decreased
cardiovascular response to exercise.  Smoking is also believed to produce
harmful effects on peripheral muscles. All these effects result in decreased
exercise tolerance in smokers. Smoking itself is associated with lower
cardiovascular capacity and impaired cardiac response to exercise.
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SUMMARY
Present study is conducted to compare the  respiratory function of
treated tuberculosis patients among smokers and non smokers .
In our study most common spirometric pattern among the treated
patients was mixed pattern 58%, followed by obstruction (29%).
Among smokers the most common spirometric pattern was mixed
pattern in 58% followed by obstruction in 28 % and restriction in 8 % and
normal in 4 % (n=2).
Among non smokers normal pattern was observed in 34.5%
followed by obstruction in 33%   restriction in 20% and mixed pattern in
13%.
The mean FEV1 among smokers is 1.09 and among non smokers is 1.68.
The difference between the 2 groups is statistically significant.
The mean distance walked by non smokers was 368.16 + 30.19
meters and the mean distance walked by smokers was 313.73+40.73
meters. The difference between the 2 groups is 54.43 meters (P < 0.0001).
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CONCLUSION
1. Among post tuberculosis patients with sequelae, both the
spirometric values and the six minute walk distance were
significantly reduced in smokers when compared to non smokers.
2. In post tuberculosis patients presenting with sequelae both
spirometry and six minute walk test were helpful in assessing the
functional status and quality of life of the patients.
3. These tests may aid in planning for rehabilitation to decrease the
symptoms and improve the functional status in these patients.
4. Hence the importance of smoking cessation should be
emphasized in all the patients diagnosed with tuberculosis.
78
LIMITATIONS
Mixed disorders are difficult to diagnose based on spirometry alone.
Spirometry along with a lung volume study is needed for this. For
diagnosing a mixed pattern there should be a clear obstructive disorder in
spirometry, with low FEV 1 /FVC ratio. If the airflow obstruction is seen
along with a reduced TLC, then the reduced TLC will suggest an
additional restrictive disorder. In our study we used only spirometry to find
the restrictive disorder.
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PROFOMA
Name                    :                                                Age/sex
Address                :
Occupation          :
Contact number :
Height :               cm                     Weight :        kg BMI:
PRESENTING SYMPTOMS:
1. Cough 4. Chest pain
2. Sputum production 5. Hemoptysis
3. Breathlessness 6. Wheeze
COMORBIDITIES :
1. Diabetes 2.Hypertension
SMOKING HISTORY :
Beedi / Cigerrete                  :
Smoking index                     :
PRIOR   ATT HISTORY           :
CAT I     /        CAT II
ECG                                        :
Chest X RAY :
Number of zones involved :
Unilateral /   Bilateral         :
PATTERNS IN CHEST X RAY :
1. Fibrosis
2. Fibrocavity
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3. Bronchiectasis
4. Calcification
5. Bulla
6. Aspergilloma
7. Combined
SPIROMETRY
PARAMETERS PREDICTED PRESENT %PREDICTED
FEV1
FVC
FEV1/FVC
PEFR
IMPRESSION   :
SIX MINUTE WALK TEST:
REASON FOR DISCONTINUATION:
PARAMETERS PRE TEST POST TEST
SPO2
HEART RATE
BLOOD PRESSURE
BORG SCALE OF DYSPNEA
xg;Gjy; gbtk;
நா காசேநா ம எ ணமா ேட . த ேபா
அத ெதாட யாக என ைர ர பா உ ள எ பைத அதைன
க பத காக ைர ர ெசய ற ப ேசாதைன 6 ட நைடப
ேசாதைன ெச ெகா ள ச மத எ பைத ெத ெகா ேற .
இதனா எ த ப க ைள க இ ைல எ பைத ம வ ல
அ ேத .
இ ப
PROFOMA
Name                    : Age/sex
Address                :
Occupation          :
Contact number :
Height : cm Weight :        kg BMI:
PRESENTING SYMPTOMS:
1. Cough 4. Chest pain
2. Sputum production 5. Hemoptysis
3. Breathlessness 6. Wheeze
COMORBIDITIES :
1. Diabetes 2.Hypertension
SMOKING HISTORY :
Beedi / Cigerrete :
Smoking index :
PRIOR ATT HISTORY :
CAT I /        CAT II
ECG :
Chest X RAY :
Number of zones involved :
Unilateral / Bilateral :
PATTERNS IN CHEST X RAY :
1. Fibrosis
2. Fibrocavity
3. Bronchiectasis
4. Calcification
5. Bulla
6. Aspergilloma
7. Combined
SPIROMETRY
PARAMETERS PREDICTED PRESENT %PREDICTED
FEV1
FVC
FEV1/FVC
PEFR
IMPRESSION :
SIX MINUTE WALK TEST:
REASON FOR DISCONTINUATION:
PARAMETERS PRE TEST POST TEST
SPO2
HEART RATE
BLOOD PRESSURE
BORG SCALE OF DYSPNEA
ATT
Ganesan 63 M 159 73 28.8 Y 30 BEEDI 10 300 N N N Y N N N Y 1 2.28 1.42 62.3 2.25
Sankaran 64 M 165 65 23.8 Y 20 BEEDI 20 200 N N N Y N N Y N 1 2.72 2.26 83.1 3.53 NORMAL
Murugan 56 M 168 46 16.3 Y 25 BEEDI 30 750 Y N N Y Y N N N 2 0.96 0.48 50 1.52 MIXED
Madasamy 40 M 145 38 18.07 Y 15 BEEDI 20 300 Y Y N N N N N N 2 1.06 0.66 62.3 1.01 MIXED
Chidambaram 53 M 159 46 18.2 Y 20 BEEDI 6 120 Y Y N Y Y N N N 1 1.81 1.3 71.8 2.78 RESTRICTION
Arunachalam 40 M 159 65 25.7 Y 30 BEEDI 12 420 Y Y N Y N N N N 1 2.12 1.35 63.7 2.42 MIXED
Mayandi 66 M 159 68 26.9 Y 46 BEEDI 30 1380 Y Y N Y N N Y N 2 1.53 0.86 56.2 1.36 MIXED
Samuthiram 60 M 168 46 14.8 Y 40 BEEDI 20 800 Y Y N Y N N N N 2 1.36 0.73 53.7 1.84 MIXED
Shanmugavel 53 M 160 56 21.8 Y 48 BOTH 22 1056 Y Y N Y N N N N 2 1.48 0.85 57.4 1.76 MIXED
Ramachandran 77 M 164 58 21.5 Y 50 BOTH 20 1000 Y Y N Y N N Y N 1 1.78 1.26 68.8 1.76 MIXED
Velayutham 67 M 160 54 21.09 Y 37 BEEDI 20 740 Y Y N Y N N N N 2 1.45 0.91 62.8 1.25 MIXED
Chellappandi 67 M 145 45 21.4 Y 55 BEEDI 10 550 Y Y N Y Y N N N 2 1.01 0.69 68.3 0.93 MIXED
Anbalagan 53 M 160 80 31.2 Y 30 BEEDI 14 420 Y N N Y N N N N 2 1.96 1.60. 81.6 3.67 RESTRICTION
paramasivam 64 M 164 65 21.1 Y 30 BEEDI 10 300 Y N N N Y N N N 1 2.33 1.54 66.1 3.28 OBSTRUCTION
Anburaj 39 M 164 50 18.6 Y 7 BEEDI 14 98 Y Y N Y N N N N 2 2.68 2.18 81.3 5.59 RESTRICTION
Karuppasamy 57 M 158 47 18.8 Y 37 BEEDI 10 370 Y Y N Y N N N N 2 1.68 1.28 76.2 2.84 MIXED
Arasappan 77 M 164 59 21.9 Y 35 BEEDI 14 490 Y N N Y N N N N 2 2.03 1.01 49.8 1.47 OBSTRUCTION
Antony 57 M 155 43 17.9 Y 20 BEEDI 25 500 Y Y N Y Y N N N 1 1.44 0.89 61.8 1.11 MIXED
Chelliah 57 M 155 45 18.7 Y 37 BEEDI 10 370 Y Y N Y N Y N N 1 1.82 1.16 63.7 1.94 OBSTRUCTION
Anthony samy 55 M 168 70 24.8 Y 20 CIGERRETE 28 560 Y Y N Y N N Y N 1 2.45 1.25 51 1.69 MIXED
Thangappan 61 M 165 48 17.6 Y 30 BEEDI 20 600 Y Y N Y N N N N 2 1.7 1.22 71.8 2.89 MIXED
Narayanan 60 M 150 54 24 Y 40 BEEDI 12 480 Y Y N Y Y N N N 1 1.67 1.02 61.1 2.54 OBSTRUCTION
Paramasivam 35 M 166 48 17.4 Y 10 BOTH 14 140 Y Y N Y N N N N 2 2.81 1.87 66.5 1.35 OBSTRUCTION
Aavudaiappan 50 M 159 47 18.5 Y 30 BEEDI 24 720 Y Y N Y N Y N N 2 1.86 0.7 37.6 0.95 MIXED
Thangappan 53 M 154 51 21.5 Y 23 BEEDI 10 230 Y N N N N N N N 2 2.48 1.14 46 1.78 OBSTRUCTION
Rajamoorthy 60 M 168 50 17.7 Y 40 BEEDI 6 240 Y N N N N N N N 1 2.97 2.34 81.2 5.04 NORMAL
Balakrishnan 47 M 162 53 20.2 Y 20 CIGERRETE 12 240 Y N N Y N N N N 2 1.67 1.43 85.6 4.74 RESTRICTION
Irudhayaraj 77 M 166 52 18.8 Y 30 BEEDI 20 600 Y Y N Y N Y Y Y 2 1.73 0.77 44.5 1.29 MIXED
Balasubramanian 65 M 160 56 21.8 Y 40 BEEDI 24 960 Y Y N Y N N N N 2 1.03 0.57 55.3 1.36 MIXED
Duraipandi 55 M 162 46 17.5 Y 25 BEEDI 15 375 Y Y N Y N N N N 2 2.21 1.59 71.9 3.92 MIXED
Krishnasamy 70 M 174 58 19.1 Y 40 BOTH 15 600 Y Y N Y Y Y N N 2 2.64 1.07 40.8 1.54 OBSTRUCTION
Mani 52 M 160 53 20.7 Y 30 BEEDI 15 450 Y Y N Y N N N Y 2 2.41 1.27 52.7 2.3 OBSTRUCTION
Iyappan 45 M 164 50 18.5 Y 20 BEEDI 20 400 Y Y N Y N N N N 1 2.3 1.43 62.2 3.92 MIXED
Krishnan 60 M 160 56 21.8 Y 40 BEEDI 14 560 Y Y N Y N N N N 2 1.43 0.73 51 0.97 MIXED
Chelladurai 51 M 151 52 22.8 Y 20 BEEDI 20 400 Y Y N Y N N N N 1 1.84 1.12 60.9 1.48 OBSTRUCTION
Anandakumar 68 M 160 53 20.7 Y 45 BOTH 20 900 Y Y N Y Y N Y N 1 1.03 0.62 60.2 0.8 MIXED
Abdulkadar 62 M 164 49 18.2 Y 40 BEEDI 20 800 Y Y N Y Y N N N 2 1.47 0.97 65.9 3.31 MIXED
Ahamad shahil 58 M 165 52 19.1 Y 28 BEEDI 28 784 Y Y N Y N N Y N 2 1.35 0.74 54.8 1.71 MIXED
Anandan 60 M 157 55 22.3 Y 35 BEEDI 10 350 Y Y N Y N N N N 2 1.37 0.95 69.3 1.32 MIXED
VELU 65 M 153 49 20.9 Y 30 BEEDI 20 600 Y Y N Y N N N N 2 1.63 0.96 58.9 1.93 OBSTRUCTION
Chokalingam 70 M 164 51 18.9 Y 40 BEEDI 14 560 Y Y N Y N N Y N 1 2.37 1.16 48.9 2.58 OBSTRUCTION
Sankar 60 M 145 51 24.2 Y 40 BEEDI 14 560 Y Y N Y N N Y N 2 0.91 0.44 48.4 0.61 MIXED
ANTHONY  MUTHU 65 M 164 46 17.1 Y 30 BEEDI 10 300 Y Y N Y N N N N 1 2.01 1.2 59 3.09 OBSTRUCTION
SANKARASUBBU 72 M 170 54 18.6 Y 35 BEEDI 20 700 Y Y N Y N N N N 1 1.62 0.81 50 1.1 MIXED
MURUGAN 58 M 155 45 18.7 Y 30 BEEDI 28 840 Y Y N Y N N N N 2 1.76 0.93 52.8 1.28 MIXED
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Malaiappan 72 M 152 42 18.1 N N N N N Y N N Y N N N N 1 2.12 1.75 82.5 2.17 NORMAL
Ramar 46 M 165 66 24.2 N N N N N Y N N N N N N N 1 2.6 2.47 95 3.85 NORMAL
Parvathy 56 F 138 40 21 N N N N N Y N N Y N N N N 1 1.22 1.65 97.6 3.18 RESTRICTION
Muthukumaran 36 M 165 68 24.9 N N N N N Y Y N N N N N N 1 1.93 1.88 97.4 3.6 RESTRICTION
Aavudaiammal 55 F 153 57 24.3 N N N N N Y Y N N N N N N 2 2.01 1.2 59.7 3.09 OBSTRUCTION
Mookammal 45 F 154 48 20.2 N N N N N Y Y N N Y N N N 2 1.64 1.13 68.9 2.01 MIXED
Jayakumari 62 F 148 36 16.4 N N N N N N Y N N N N N N 1 2 1.64 82 3.4 NORMAL
Malathy 67 F 146 38 17.8 N N N N N Y Y N Y N N N N 1 1.87 1.27 67.9 2.78 OBSTRUCTION
Chitra 43 F 147 60 28.9 N N N N N Y N N N N N N N 1 2.13 1.3 64.8 3.07 OBSTRUCTION
Essakiammal 57 F 148 58 26.4 N N N N N Y Y N Y N N Y N 2 1.41 0.89 63.1 1.61 MIXED
Mariappan 39 M 165 61 22.4 N N N N N N N N N N N N N 1 2.68 2.18 81.3 6.63 RESTRICTION
Thangaraj 57 M 170 74 25.6 N N N N N N N N N N N N N 1 2.79 2.09 74.9 4.81 OBSTRUCTION
Balasubramaniyan 34 M 167 64 22.9 N N N N N N N N N N N N N 1 2.54 2.4 94.5 4.45 RESTRICTION
Pandaram 67 M 157 36 20.6 N N N N N N N N N N N Y N 1 1.95 1.6 82.05 3.34 NORMAL
Madakani 67 F 132 37 21.2 N N N N N N N N N N N N N 1 1.08 0.96 88.8 1.85 NORMAL
Jabakani 57 F 143 33 16.14 N N N N N Y N N N N N N N 1 1.52 1.44 94.7 3.35 NORMAL
Raveendran 57 M 175 44 14.3 N N N N N Y Y N Y N N N N 1 2.75 2.53 92 6.61 RESTRICTION
Raheem 48 M 160 49 19.1 N N N N N Y N N N N N N N 1 2.25 1.95 86.7 4.55 NORMAL
Rajalakshmi 57 F 145 44 20.9 N N N N N N N N Y N N N N 1 1.74 1.42 81.6 3.65 NORMAL
Thangam 48 F 157 42 17.04 N N N N N Y Y N Y Y N N N 1 2.11 1.54 73 2.65 OBSTRUCTION
Muthusamy 67 M 160 41 16 N N N N N N N N Y N N N N 1 2.3 1.83 80 3.42 NORMAL
Baskaran 58 M 165 51 18 N N N N N Y Y N N N N N N 1 2.75 1.81 65.8 3.22 OBSTRUCTION
Lakshmanan 39 M 165 72 26.4 N N N N N Y Y N Y Y N N N 2 2.78 1.96 70.5 2.72 MIXED
Iyyappan 27 M 162 50 19 N N N N N Y Y N N N N N N 1 2.87 2.3 80.1 5.31 NORMAL
Veerammal 38 F 140 30 15.3 N N N N N N N N Y N N N N 1 1.66 1.46 88 2.95 NORMAL
Arumugam 67 M 156 66 27.1 N N N N N Y Y N Y Y N N N 1 2.09 1.29 61.7 2 OBSTRUCTION
Shahul ahamed 68 M 165 60 20.4 N N N N N Y Y N N N N Y N 1 1.78 1.47 82.6 2.93 RESTRICTION
Aanandaraj 66 M 156 58 23.8 N N N N N N N N Y N N N N Y 1.68 1.41 83.9 3.94 NORMAL
Anbalagan 60 M 161 58 22.3 N N N N N Y N N N N N Y N 1 2.46 1.94 80.1 2.95 NORMAL
Perumal 57 M 164 45 16.7 N N N N N Y Y N Y N N N N 1 3.03 1.61 53.1 3.02 RESTRICTION
Thangammal 46 F 165 47 17.3 N N N N N Y Y N Y Y N Y N 2 1.53 0.91 60.1 1.67 MIXED
Arumugam 67 M 159 37 14.6 N N N N N Y Y N Y N N N N 1 2.32 1.42 62.9 2.93 OBSTRUCTION
Duraipandian 55 M 162 46 17.5 N N N N N Y N N Y N N N N 2 2.21 1.59 71.9 3.92 MIXED
Indira 27 F 149 45 20.2 N N N N N N N N Y N N N N 1 1.86 1.78 95.7 4.57 RESTRICTION
Madasamy 39 M 175 69 22.5 N N N N N Y N N N N N N N 1 3.71 2.96 81.4 6.2 NORMAL
Sudalaipandi 45 M 155 53 22 N N N N N Y Y N Y N N N N 1 2.84 1.93 98 3.62 OBSTRUCTION
Murugan 56 M 146 54 25.3 N N N N N Y N N N N N N N 1 1.7 1.64 96.5 2.24 RESTRICTION
Abdul Kabir 45 M 156 40 16.4 N N N N N Y Y N N N N N N 1 2.01 1.2 59.7 3.09 OBSTRUCTION
Rajendran 64 M 158 41 16.4 N N N N N Y Y N N N N N N 2 1.88 1.03 54.8 1.45 OBSTRUCTION
Arumugam 53 M 157 40 16.3 N N N N N Y N N N N N N N 1 2.35 1.88 80.1 4.03 NORMAL
Madar Mohideen 80 M 170 50 17.3 N N N N N N N N Y N N N Y 1 1.92 1.82 97.8 4.06 RESTRICTION
Parimala 38 F 150 52 23.1 N N N N N Y Y N N N N N N 1 2.1 1.76 83.8 3.33 NORMAL
Sundar singh 67 M 170 50 17.3 N N N N N Y Y N Y N N N N 1 3.16 1.95 61.7 387 OBSTRUCTION
Ammaponnu 59 F 147 49 22.7 N N N N N Y Y N N N N N N 1 2.61 1.58 60.5 3.21 OBSTRUCTION
Kaarman 28 M 160 65 25.3 N N N N N Y Y N N N N N N 1 3.75 2.23 59.5 4.48 OBSTRUCTION
Subbiah 65 M 160 45 17.5 N N N N N Y Y N Y N N N N 2 2.43 1.47 60.5 2.61 OBSTRUCTION
Sudalaimuthu 56 M 160 44 17.2 N N N N N Y N N N N N N N 1 2.26 1.82 96.4 3.75 NORMAL
Esakkiammal 43 F 157 36 14.6 N N N N N Y Y N N N N N N 1 2.18 1.79 82.1 4.13 NORMAL
Krishnamoorthy 45 M 153 44 18.8 N N N N N Y Y N Y N N N N 1 2.39 1.4 58.6 2.43 OBSTRUCTION
Petchiammal 58 F 145 36 17.1 N N N N N Y N N N N N N N 1 1.77 1.51 80.2 3.45 NORMAL
Mariappan 39 M 165 61 22.4 N N N N N Y N N Y N N N N 1 2.68 2.18 81.3 6.63 RESTRICTION
Esakkiammal 48 F 163 40 15.1 N N N N N Y Y N Y N Y N N 1 2.2 1.71 77.7 3.62 MIXED
Nisha 67 F 150 66 29.3 N N N N N Y Y N N N N N N 2 2.23 1.24 55.6 2.58 OBSTRUCTION
Ramasubbu 67 M 170 68 23.5 N N N N N Y Y N Y N N Y N 1 2.39 1.88 78.7 40.93 MIXED
Sathya 46 F 147 60 27.7 N N N N N Y Y N N N Y N N 1 2.13 1.38 64.8 2.71 OBSTRUCTION
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96 93 92 102 126 82 97 128 80 96 2 5 320 BOTH U/L 1 N N N Y N N N
97 96 74 79 130 80 97 136 82 100 2 4 365 LEFT U/L 1 N N Y N N N N
94 90 92 116 110 68 82 124 76 92 3 7 270 BOTH B/L 4 Y N N Y Y N Y
96 92 86 112 110 80 90 122 88 99 3 8 244/STOP BOTH B/L 3 Y N Y N Y N Y
96 92 87 92 122 80 91 136 84 100 2 5 325 LEFT U/L 1 Y N N N N N N
97 93 76 88 116 80 92 126 88 101 3 6 335 LEFT U/L 1 Y N N N N N N
95 90 85 104 130 82 98 140 90 107 3 7 310 RIGHT U/L 2 Y N N Y N N Y
94 90 96 118 110 70 83 126 82 97 3 7 250/STOP BOTH B/L 4 Y N N Y Y N Y
94 89 90 102 106 76 86 118 80 93 3 8 280 RIGHT U/L 2 Y N Y N N N Y
97 94 98 110 130 90 103 138 94 109 3 6 310 RIGHT U/L 2 Y N N Y Y N Y
96 93 86 98 132 74 93 138 78 98 2 6 310 RIGHT U/L 2 Y N Y N N N Y
96 93 96 118 108 64 78 116 76 89 2 5 310 RIGHT B/L 3 Y N N Y N N Y
97 95 78 86 122 82 95 130 90 103 2 4 350 LEFT U/L 1 Y N N N N N N
97 95 68 78 112 70 84 120 74 89 2 4 360 LEFT U/L 2 N N Y N N N N
98 97 80 88 110 80 90 114 80 91 2 4 356 RIGHT U/L 1 Y N N N N N N
98 96 88 96 120 82 94 126 86 99 2 5 320 RIGHT U/L 1 Y N Y N N N Y
97 93 74 88 130 80 96 136 88 104 2 4 320 RIGHT U/L 1 Y N Y N N N Y
98 95 88 98 122 84 96 132 90 104 3 7 310 BOTH B/L 2 Y N Y Y N N Y
98 97 78 88 118 74 90 112 74 87 2 4 360 RIGHT U/L 2 N N N Y N N N
95 90 96 122 122 74 90 132 82 99 3 7 296 BOTH B/L 2 Y N Y Y N N Y
96 92 94 105 110 80 90 114 76 89 2 5 336 BOTH B/L 2 N N N Y N N N
97 94 80 92 130 80 96 136 82 100 2 4 325 RIGHT U/L 1 N N N Y N N N
97 95 84 96 110 80 90 116 82 93 2 4 360 RIGHT U/L 2 N N N Y N N N
95 91 90 112 126 74 91 132 80 97 3 5 235/STOP BOTH B/L 3 Y Y N Y Y N Y
98 96 82 94 120 76 90 124 76 92 2 4 325 BOTH B/L 2 N N N Y N N N
97 96 80 88 128 80 96 130 82 98 Y 3 360 LEFT U/L 1 Y N N N N N N
97 92 82 102 100 70 80 108 74 85 2 4 338 RIGHT U/L 2 Y Y N N N N Y
96 91 92 103 110 80 95 116 82 93 3 7 315 BOTH B/L 4 Y N Y Y N N Y
94 88 90 128 130 90 103 140 94 109 3 8 285 BOTH B/L 3 Y N Y N N Y Y
97 95 92 118 110 72 85 114 74 87 2 5 345 BOTH B/L 3 N N N Y N Y Y
95 90 94 120 130 76 94 138 84 102 3 8 280 RIGHT U/L 3 Y N Y N N N Y
97 94 86 102 120 70 87 128 74 92 2 5 325 LEFT U/L 2 N N N Y N N N
98 96 80 88 120 80 93 126 78 94 2 6 360 RIGHT U/L 2 Y N N N N Y Y
95 92 88 102 110 76 87 120 84 96 3 7 310 LEFT U/L 3 Y N N N N Y Y
96 94 80 88 112 78 89 120 78 92 2 4 380 LEFT U/L 2 Y N N Y N N Y
96 93 90 116 110 70 83 122 78 93 3 8 272/STOP LEFT U/L 4 Y N N N N Y Y
96 92 92 114 120 76 91 132 82 99 3 8 265/STOP BOTH B/L 3 Y Y N N N Y Y
96 93 90 108 116 76 89 126 84 98 3 8 265/STOP BOTH B/L 4 Y Y N Y N N Y
97 94 86 100 110 68 82 122 72 89 2 6 316 BOTH B/L 3 Y N Y N N N Y
97 95 82 93 116 78 91 120 82 95 2 5 340 BOTH B/L 2 N N N Y N N N
98 95 74 82 126 78 94 132 84 100 3 6 390 RIGHT U/L 1 N N N Y N N N
94 89 98 126 108 64 79 120 72 88 3 7 220/STOP BOTH B/L 4 Y N Y Y N N Y
97 95 84 96 120 78 92 132 82 99 2 5 340 RIGHT U/L 2 N N N Y N N N
95 90 88 120 130 80 97 142 92 109 3 9 240/STOP BOTH B/L 4 Y Y N Y N N Y
96 93 94 118 110 74 86 122 80 94 3 8 290 BOTH B/L 3 Y Y N N N N Y
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97 95 84 90 130 80 97 134 82 99 Y 3 325 RIGHT U/L 1 Y N N N N N N
98 98 78 84 120 70 87 122 70 87 Y 3 395 RIGHT U/L 1 Y N N N N N N
96 95 86 94 110 80 90 114 84 94 2 5 340 RIGHT U/L 1 Y N N N N N N
93 90 94 112 120 76 91 130 82 98 2 5 330 BOTH B/L 2 Y N N N N N N
95 93 87 96 100 76 84 116 80 92 3 6 310 LEFT U/L 1 N N N Y N N N
96 93 92 106 116 76 89 122 80 94 3 7 300 BOTH B/L 2 Y N Y Y N N Y
97 97 72 76 110 78 89 114 78 90 Y 3 335 LEFT U/L 1 Y N N N N N N
96 93 79 92 130 90 103 138 94 109 2 4 385 RIGHT U/L 1 N N N Y N N N
99 97 79 86 100 70 80 108 72 84 Y 3 405 LEFT U/L 1 N N N Y N N N
99 97 92 104 120 76 91 126 78 94 2 7 320 LEFT U/L 2 Y N Y N N N Y
98 96 88 106 116 74 88 120 72 88 2 3 390 RIGHT U/L 1 N N N Y N N N
99 98 86 90 122 80 94 124 80 95 2 5 418 LEFT U/L 1 N N N Y N Y Y
98 98 90 94 110 80 90 114 80 91 Y 3 356 LEFT U/L 1 Y N N N N N N
97 96 90 94 122 76 91 124 78 93 Y 3 385 LEFT U/L 1 Y N N N N N N
97 96 80 84 116 78 91 120 78 92 2 4 360 RIGHT U/L 1 N N N Y N N N
98 98 72 78 116 74 88 118 76 90 Y 3 390 LEFT U/L 1 N N N N N Y N
97 95 80 96 120 74 89 130 78 95 2 5 385 RIGHT U/L 1 N N N N Y N N
98 97 84 96 130 74 93 134 80 98 2 5 420 LEFT U/L 1 Y N N N N N N
98 98 68 74 130 82 98 136 84 101 2 5 370 RIGHT U/L 1 Y N N N N N N
98 97 72 78 110 80 90 116 82 93 2 6 380 RIGHT U/L 1 Y N N Y N N Y
97 96 74 78 130 76 94 130 78 95 2 4 390 RIGHT U/L 1 N N N Y N N N
97 95 82 90 126 78 94 130 72 91 2 5 345 LEFT U/L 2 N N N Y N N N
97 95 68 78 130 80 97 138 86 103 3 6 370 BOTH B/L 2 Y N Y N N N Y
99 98 76 84 112 76 88 116 76 89 Y 3 410 LEFT U/L 1 N N N Y N N N
98 98 82 86 100 70 80 106 74 85 2 5 395 RIGHT U/L 1 Y N N N N N N
96 93 84 96 116 66 83 128 68 88 3 6 355 RIGHT U/L 1 N N N Y N N N
97 95 88 95 130 84 99 136 86 103 2 5 355 LEFT U/L 2 N N N Y N N N
97 96 80 84 114 74 88 116 72 87 Y 3 380 RIGHT B/L 1 N N N Y N N N
97 96 85 90 108 70 83 112 72 85 Y 3 360 LEFT U/L 1 Y N N N N N N
96 93 82 98 120 74 89 134 80 98 3 5 340 LEFT U/L 2 Y N N Y N N Y
97 94 84 96 110 72 85 118 78 91 3 7 286 BOTH B/L 3 Y N Y N N N Y
97 95 79 86 126 80 95 130 82 98 2 4 340 RIGHT U/L 2 N N N Y N N N
99 97 82 90 110 80 90 112 82 92 2 5 360 RIGHT U/L 2 Y N N N Y Y Y
98 97 84 96 120 70 87 124 70 88 2 4 385 LEFT U/L 1 Y N Y N N N Y
99 98 80 86 124 76 92 128 76 93 2 4 420 LEFT U/L 1 Y N N N N N N
97 94 88 96 120 76 91 124 78 93 2 4 365 RIGHT U/L 1 Y N N Y N N Y
97 95 80 88 112 80 91 114 80 91 2 5 381 LEFT U/L 1 Y N N N N N N
97 95 84 92 130 90 103 134 92 106 2 5 370 RIGHT U/L 2 N N N Y N N N
96 93 90 98 110 80 90 116 86 96 2 4 358 RIGHT U/L 1 Y N Y N N N Y
98 97 80 86 126 80 95 128 80 96 Y 3 400 RIGHT U/L 1 Y N N N N N N
97 96 90 98 140 90 107 144 90 108 Y 3 390 RIGHT U/L 1 Y N N N N N N
98 97 88 94 114 74 87 118 76 90 Y 3 380 LEFT U/L 1 Y N N N N N N
97 96 90 103 132 93 105 136 90 105 2 5 395 LEFT U/L 1 N N N Y N N N
97 96 82 98 100 60 73 108 64 79 2 5 350 LEFT U/L 2 N N N Y N N N
98 97 84 92 120 82 95 124 82 96 2 4 390 RIGHT U/L 1 N N N Y N N N
98 95 82 87 122 78 92 128 80 96 3 7 340 LEFT U/L 1 Y N N Y N N Y
97 96 84 88 110 70 83 112 70 84 Y 3 395 LEFT U/L 1 Y N N N N N N
99 97 74 80 122 82 95 124 80 95 Y 3 410 LEFT U/L 1 Y N N N N N N
97 95 78 86 112 76 88 118 80 93 3 5 343 RIGHT U/L 2 N N N Y N N N
98 97 82 88 110 70 83 114 70 85 Y 3 374 RIGHT U/L 1 Y N N N N N N
98 97 84 88 120 80 93 122 80 94 2 4 386 LEFT U/L 1 Y N N N N N N
98 96 78 86 110 76 87 116 78 91 3 7 370 LEFT U/L 2 Y N Y N N N Y
98 97 86 98 130 86 101 140 92 108 3 7 336 RIGHT U/L 2 Y N N Y N N Y
97 95 84 90 110 82 91 116 84 95 3 7 358 LEFT U/L 2 Y N Y N N N Y
97 96 82 80 100 70 80 106 72 83 2 4 368 RIGHT U/L 1 N N Y N N N N
NON SMOKERS
Pulmonary Function Test Results
DEPT OF PULMONARY MEDICINE
TIRUNELVELI MEDICAL COLLEGE
TIRUNELVELI-11
Visit date 11/19/2016
Patient code 9799
Surname
Name
Date of birth
Ethnic group
Smoke
Patient group
sankarasubbu
s
11/19/1944
South indian
Age 72
Gender Male
Height, cm 170
Weight, kg 54
BMI 18.69
Pack-Year
Interpretation
Very Severe Obstruction
Best values from all loops
PRE
Predicted
Parameters Pred PRE %Pred POST %Chg
FEV1
FEV1%
PEF
FVC
L
%
L/s
L
2.34
79.4
7.47
2.98
0.81
50.00
1.10
1.62
35
63
15
54
PRE Trial date 11/19/2016   12:18:04 PM
FVC FEV1 FEV1%
PRE PRE PRE
Flow / Volume Loop and Volume / Time Curve
%Pred %ChgPOST#1PRE # 3PRE # 2%PredPRE # 1PredParameters
FEV1 L 2.34 0.81 35 0.73 0.76
FEV1/FVC % 79.4 50.0 63 46.8 52.1
PEF L/s 7.47 1.10 15 1.07 1.10
ELA Years 72 132 183 135 134
FEF2575 L/s 2.71 0.56 21 0.49 0.47
FVC L 2.98 1.62 54 1.56 1.46
FET s 6.00 4.65 78 4.17 5.14
FEV1/VC % 79.4
FEF25 L/s 6.82 0.83 12 0.75 0.81
FEF50 L/s 3.45 0.52 15 0.42 0.53
FEF75 L/s 1.13 0.29 26 0.26 0.25
MVV(cal) L/min 106.0 28.4 27 25.6 26.6
FIF50 L/s
R50 %
Conclusion / Medical report
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Pulmonary Function Test Results
DEPT OF PULMONARY MEDICINE
TIRUNELVELI MEDICAL COLLEGE
TIRUNELVELI-11
Visit date 11/14/2016
Patient code 9578
Surname
Name
Date of birth
Ethnic group
Smoke
Patient group
arunachalam
s
5/14/1976
South indian
Age 40
Gender Male
Height, cm 159
Weight, kg 65
BMI 25.71
Pack-Year
Interpretation
Obstruction with Possible Restriction
Significant Bronchodil. (FEV1 < 80%Pred. )
WARNING: FEF2575 POST = 47%Pred.
Best values from all loops
PRE
POST
Predicted - Knudson
Parameters Pred PRE %Pred POST %Chg
FEV1
FEV1%
PEF
FVC
L
%
L/s
L
2.51
84.7
7.55
3.00
1.35
63.70
2.42
2.12
54
75
32
71
1.76
75.20
3.85
2.34
30
18
59
10
PRE Trial date 11/14/2016   9:06:32 AM
FVC FEV1 FEV1%
PRE PRE PRE
POST POST POST
Flow / Volume Loop and Volume / Time Curve
%Pred %ChgPOST#1PRE # 3PRE # 2%PredPRE # 1PredParameters
FEV1 L 2.51 1.34 53 1.35 1.76 70 31
FEV1/FVC % 84.7 63.2 75 67.8 75.2 89 19
PEF L/s 7.55 2.42 32 1.91 3.85 51 59
ELA Years 40 86 215 86 70 175 -19
FEF2575 L/s 3.24 0.99 31 1.06 1.51 47 53
FVC L 3.00 2.12 71 1.99 2.34 78 10
FET s 6.00 3.61 60 3.30 3.67 61 2
FEV1/VC % 84.7
FEF25 L/s 6.97 1.83 26 1.91 2.73 39 49
FEF50 L/s 3.87 0.94 24 1.05 1.63 42 73
FEF75 L/s 1.53 0.44 29 0.51 0.71 47 61
MVV(cal) L/min 119.0 46.9 39 47.3 61.6 52 31
FIF50 L/s
R50 %
Conclusion / Medical report
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